Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 50,000 full-time employees. The firm manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
Mr. David Ricks est le Chairman of the Board de Eli Lilly and Co, il a rejoint l'entreprise depuis 2012.
Quelle est la performance du prix de l'action LLY ?
Le prix actuel de LLY est de $965.5, il a diminué de 0.16% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Eli Lilly and Co ?
Eli Lilly and Co appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quel est la capitalisation boursière de Eli Lilly and Co ?
La capitalisation boursière actuelle de Eli Lilly and Co est de $912.2B
Est-ce que Eli Lilly and Co est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 34 analystes ont établi des notations d'analystes pour Eli Lilly and Co, y compris 9 achat fort, 17 achat, 9 maintien, 0 vente et 9 vente forte